Biopharmaceuticals Market Research Reports & Industry Analysis
Biopharmaceuticals are a class of drugs produced using living organisms or their cellular components to treat various medical conditions. By providing highly targeted and sophisticated therapeutic options, biopharmaceuticals have revolutionized the field of medicine. If you are in search of comprehensive and objective data on this fast-growing market, you have come to the right place. MarketResearch.com offers hundreds of biopharmaceuticals industry reports published by leading research firms.
New Biopharmaceuticals Market Research
- Use our reports to explore diverse markets in the biopharmaceuticals industry, from biosimilars to enzymes to antibodies.
- Gain invaluable insights, including biopharmaceuticals market size, growth, and industry trends.
- Get up to speed on the latest technological breakthroughs, opportunities, and market-entry strategies.
Proven Expertise in the Field of Market Research
With a track record spanning more than two decades, MarketResearch.com is a trusted source for market research. We serve top-tier investment banks, management consulting firms, and Fortune 500 multinational corporations. Our dedicated research specialists are here to provide recommendations and guidance throughout your research process. Improve your knowledge and enhance your strategies with biopharmaceutical market research from MarketResearch.com today.
Biopharmaceuticals Industry Research & Market Reports
-
Biopharmaceuticals – A Global Market Overview
... complex molecules, including proteins, nucleic acids, and vaccines, in contrast to traditional small-molecule drugs. Biopharmaceutical products are developed to address chronic, complex, and rare illnesses, providing targeted treatments that conventional drugs often lack. They are ... Read More
-
Bioburden Testing
... CAGR of 11.3% over the analysis period 2024-2030. Bioburden Testing Consumables, one of the segments analyzed in the report, is expected to record a 11.8% CAGR and reach US$1.5 Billion by the end of the ... Read More
-
Biosimilars
... 20.0% over the analysis period 2024-2030. Recombinant Non-glycosylated Proteins, one of the segments analyzed in the report, is expected to record a 20.4% CAGR and reach US$62.4 Billion by the end of the analysis period. ... Read More
-
Biopharmaceuticals
... 12.1% over the analysis period 2024-2030. Monoclonal Antibody, one of the segments analyzed in the report, is expected to record a 10.0% CAGR and reach US$288.2 Billion by the end of the analysis period. Growth ... Read More
-
Anti-inflammatory Drugs Market Size, Share, and Analysis, By Drug Type (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics, and Corticosteroids), By Application (Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease (IBD), and Others), By Route of Administration (Oral, Topical, Injection, and Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034
... and Others), By Route of Administration (Oral, Topical, Injection, and Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast ... Read More
-
Electronic Laboratory Notebooks (ELNs)
... 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Cross-disciplinary ELNs, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$801.2 Million by the ... Read More
-
Biopharmaceutical Bioseparation Systems
... at a CAGR of 10.9% over the analysis period 2024-2030. Chromatography Technology, one of the segments analyzed in the report, is expected to record a 10.2% CAGR and reach US$15.8 Billion by the end of ... Read More
-
Single-Use Bioprocessing
... CAGR of 20.8% over the analysis period 2024-2030. Single-Use Media Bags & Containers, one of the segments analyzed in the report, is expected to record a 22.6% CAGR and reach US$29.9 Billion by the end ... Read More
-
Autoimmune Disease Therapeutics
... at a CAGR of 3.8% over the analysis period 2024-2030. Anti-inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$183.0 Billion by the end of ... Read More
-
PEGylated Proteins
... CAGR of 9.1% over the analysis period 2024-2030. PEGylated Proteins Consumables, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$1.3 Billion by the end of the ... Read More
-
Bioreactors and Fermenters
... at a CAGR of 10.9% over the analysis period 2024-2030. Single-use Bioreactors, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$3.2 Billion by the end of ... Read More
-
Biologics
... 8.2% over the analysis period 2024-2030. Recombinant Therapeutic Proteins, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$271.3 Billion by the end of the analysis period. ... Read More
-
Biopharmaceutical Logistics
... CAGR of 4.8% over the analysis period 2024-2030. Cold Chain Logistics, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$37.9 Billion by the end of the ... Read More
-
Spine Biologics
... CAGR of 4.4% over the analysis period 2024-2030. Spinal Allografts, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$1.4 Billion by the end of the analysis ... Read More
-
Biopharmaceutical Fermentation Systems
... at a CAGR of 4.5% over the analysis period 2024-2030. Upstream Products, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$6.5 Billion by the end of ... Read More
-
Biopharmaceuticals Manufacturing Consumables Testing
... 2030, growing at a CAGR of 11.1% over the analysis period 2024-2030. Compendial & Multi Compendial Laboratory Testing, one of the segments analyzed in the report, is expected to record a 10.7% CAGR and reach ... Read More
-
North America Process Automation and Instrumentation Market Size, Share, Trends & Analysis by Instrument (Field Instrument, Control Valve, Analyzer), by Solution (APC, DCS, HMI, MES, PLC, Safety Automation, SCADA), by End User (Oil and Gas, Food and Beverage, Pharmaceutical and Biopharma, Chemical and Petrochemical) and Region, with Forecasts from 2024 to 2034.
... of smart manufacturing practices. The market is projected to grow from USD XXX.XX million in 2024 to USD XX.XX million by 2034, at a compound annual growth rate (CAGR) of XX.XX%. Key growth drivers include: ... Read More
-
U.S. Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule (Biologics & Biosimilars, Conventional Drugs), By Product, By Type, By Route Of Administration, By Disease, By Age Group, By Distribution Channel, And Segment Forecasts, 2025 - 2030
... an estimated value of USD 883.97 billion by 2030. This growth can be attributed to the rising prevalence of chronic diseases, increasing geriatric population, growing healthcare expenditure by government organizations, and extensive efforts to improve ... Read More
-
Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Global Market Opportunities And Strategies To 2033
... Application: Crohn’s Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis4) By Trastuzumab Biosimilars (By Application): Adjuvant Breast Cancer; Metastatic Breast Cancer; Metastatic Gastric CancerCovering: Amgen Inc.; Samsung Biologics Co., Ltd.; Biocon Limited; ... Read More
-
Global Biologics and Biosimilars Market Growth (Status and Outlook) 2025-2031
... expected to grow at a CAGR of 9.0% from 2025 to 2031. Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth ... Read More
-
Global Aflibercept Biosimilars Competitive Landscape Professional Research Report 2025
... used primarily to treat various retinal diseases, including age-related macular degeneration (AMD) and diabetic retinopathy. These biosimilars undergo rigorous testing to demonstrate their equivalence in terms of safety, efficacy, and quality to the reference product, ... Read More
-
Global Biologics and Biosimilars Competitive Landscape Professional Research Report 2025
... used for the treatment of various diseases, including cancer, autoimmune disorders, and genetic diseases. Biologics are often highly complex and require specialized manufacturing techniques to ensure their safety, efficacy, and consistency. Biosimilars, on the other ... Read More
-
Global Erythropoietin Drugs Market - 2025-2032
... forecast period 2025-2032. Erythropoietin drugs are synthetic forms of the naturally occurring hormone erythropoietin (EPO), which is primarily produced by the kidneys. EPO plays a crucial role in regulating red blood cell production in the ... Read More
-
Anti-Obesity Drugs Market by Type of Molecule (Biologics and Small Molecules), Active Compound Used (Tirzepatide, Semaglutide, Retatrutide, Survodutide, Cagrilintide and Semaglutide, Orforglipron, Liraglutide and Other Active Compounds), Mechanism of Action (GLP-1 Agonist / GIP Agonist, GLP-1 Agonist / GCGR Agonist, GLP-1 Agonist, GLP-1 Agonist / Amylin Analogue, GLP-1 / GCGR / GIP Agonist and Other Mechanisms of Action), Type of Agonist (Single-Agonist, Dual-Agonist and Tri-Agonist), Action Pathway (Centrally Acting, Peripherally Acting and Centrally Acting, and Peripherally Acting), Route of Administration (Oral and Parenteral), Geographical Regions (North America, Europe, Asia-Pacific and Latin America), Sales Forecast and Key Players: Industry Trends and Global Forecasts, till 2035
... CAGR of 21. 1% during the forecast period, till 2035. The opportunity for anti-obesity drugs market has been distributed across the following segments: Type of Molecule Biologics Small Molecules Active Compound Used Tirzepatide Semaglutide Retatrutide ... Read More
-
Global Biopharmaceutical Contract Manufacturing Market - Focused Insights 2024-2029
... of the leading CMO invested over $1 billion investment in biomanufacturing in France to enhance medicine production capabilities in France. In 2023, GTP Bioways opened two new biopharmaceutical production facilities in France. In 2024, Lonza ... Read More
Research Assistance
